Nanovision and Genpharm Partner to Introduce Phased Array CT
Dubai, UAE — Medical imaging innovator Nanovision and UAE-based specialty healthcare company Genpharm have signed a strategic memorandum of understanding (MoU) to explore introducing Nanovision’s Phased Array CT technology to the Middle East and North Africa (MENA) region.
The partnership aims to combine Nanovision’s next-generation imaging technology with Genpharm’s regional market access expertise and clinical network to support the introduction of this new CT imaging architecture across the region.
Unlike conventional CT systems that rely on high-speed mechanical gantry rotation for data acquisition, Phased Array CT employs electronically controlled multiple X-ray sources, fundamentally redesigning the CT acquisition architecture. This approach enables higher spatial resolution, richer anatomical information, and new possibilities for dynamic imaging.
A recent study published in the leading medical imaging journal Radiology demonstrated that a dual-ring, multi-source stationary CT prototype significantly improved the visualization of fine pulmonary structures compared with conventional helical CT at comparable radiation doses, allowing radiologists to observe more distal bronchial branches and finer lung structures.
Nanovision’s CompoundEye 24, the world’s first Phased Array CT system, received regulatory approval from China’s National Medical Products Administration (NMPA) on December 31, 2025. The company has also submitted its EU MDR certification application as part of its international regulatory strategy.
Li Yuan, Chief Operations Officer of Nanovision, said:
“Phased Array CT represents a fundamentally new architecture for medical imaging. By capturing richer anatomical information, this technology has the potential to support earlier disease detection and more precise clinical assessment. We are pleased to partner with Genpharm, whose regional expertise and healthcare network will be instrumental in bringing this innovation to providers and patients across the MENA region once regulatory approvals are obtained.”
Adeeb Al Attar, Managing Director of Genpharm, said:
“Our collaboration with Nanovision marks the introduction of this advanced imaging innovation to the Middle East and North Africa. This partnership reinforces our commitment to enabling access to leading global medical technologies and contributing to the advancement of regional healthcare systems.”
Under the MoU, the two companies will explore collaboration in regulatory strategy, market entry and clinical engagement.
The MENA healthcare market, covering countries such as Saudi Arabia, the United Arab Emirates and Egypt, serves a population of more than 500 million people. Industry forecasts estimate that the region’s healthcare sector will grow from $256.5 billion in 2025 to $412.2 billion by 2032, representing a compound annual growth rate of approximately 7%.
About Nanovision
Nanovision is a medical technology company focused on developing next-generation medical imaging systems. Its Phased Array CT platform, including the CompoundEye 24 system, replaces conventional mechanical gantry rotation with a multi-source electronic scanning architecture. This design enables new levels of spatial resolution and data acquisition capability, providing high-quality imaging data to support precision medicine and future medical AI applications.